Showing 1 - 7 results of 7 for search 'Paul J. Pockros', query time: 0.04s Refine Results
  1. 1
    Review: New direct-acting antivirals in the development for hepatitis C virus infection

    Review: New direct-acting antivirals in the development for hepatitis C virus infection by Paul J. Pockros

    Published 2010-05-01
    Get full text
    Article
  2. 2
    Novel emerging treatments for hepatitis C infection: a fast-moving pipeline

    Novel emerging treatments for hepatitis C infection: a fast-moving pipeline by Ara A. Kardashian, Paul J. Pockros

    Published 2017-02-01
    Get full text
    Article
  3. 3
    Morphometry Confirms Fibrosis Regression From Sustained Virologic Response to Direct‐Acting Antivirals for Hepatitis C

    Morphometry Confirms Fibrosis Regression From Sustained Virologic Response to Direct‐Acting Antivirals for Hepatitis C by Jason J. Pan, Fei Bao, Emma Du, Chase Skillin, Catherine T. Frenette, Jill Waalen, Lakshmi Alaparthi, Zachary D. Goodman, Paul J. Pockros

    Published 2018-11-01
    Get full text
    Article
  4. 4
    Ombitasvir, Paritaprevir, Ritonavir, and Dasabuvir With or Without Ribavirin in Patients With Kidney Disease

    Ombitasvir, Paritaprevir, Ritonavir, and Dasabuvir With or Without Ribavirin in Patients With Kidney Disease by David E. Bernstein, Albert Tran, Paul Martin, Kris V. Kowdley, Marc Bourliere, Mark S. Sulkowski, Paul J. Pockros, Boris Renjifo, Deli Wang, Diana L. Shuster, Daniel E. Cohen, Ira M. Jacobson

    Published 2019-02-01
    Get full text
    Article
  5. 5
    Efficacy and Safety of Cenicriviroc in Patients With Primary Sclerosing Cholangitis: PERSEUS Study

    Efficacy and Safety of Cenicriviroc in Patients With Primary Sclerosing Cholangitis: PERSEUS Study by Bertus Eksteen, Christopher L. Bowlus, Aldo J. Montano‐Loza, Eric Lefebvre, Laurent Fischer, Pamela Vig, Eduardo Bruno Martins, Jawad Ahmad, Kidist K. Yimam, Paul J. Pockros, Jordan J. Feld, Gerald Minuk, Cynthia Levy

    Published 2021-03-01
    Get full text
    Article
  6. 6
    Efficacy and Safety of Ombitasvir/Paritaprevir/Ritonavir in Patients With Hepatitis C Virus Genotype 1 or 4 Infection and Advanced Kidney Disease

    Efficacy and Safety of Ombitasvir/Paritaprevir/Ritonavir in Patients With Hepatitis C Virus Genotype 1 or 4 Infection and Advanced Kidney Disease by Eric Lawitz, Edward Gane, Eric Cohen, John Vierling, Kosh Agarwal, Tarek Hassanein, Parvez S. Mantry, Paul J. Pockros, Michael Bennett, Nyingi Kemmer, Giuseppe Morelli, Jiuhong Zha, Deli Wang, Nancy S. Shulman, Daniel E. Cohen, K. Rajender Reddy

    Published 2019-02-01
    Get full text
    Article
  7. 7
    Balapiravir plus peginterferon alfa-2a (40KD)/ribavirin in a randomized trial of hepatitis C genotype 1 patients(♦♦ Grant Support: This study was funded by Roche. The sponsor contributed to study design as well as data collection, analysis, and interpretation with input from the investigators. Writing support was provided by Blair Jarvis of Health Interactions and funded by Hoffman La-Roche Ltd. ClinicalTrials.gov Identifier: NCT00517439)

    Balapiravir plus peginterferon alfa-2a (40KD)/ribavirin in a randomized trial of hepatitis C genotype 1 patients(♦♦ Grant Support: This study was funded by Roche. The sponsor contr... by David R. Nelson, Stefan Zeuzem, Pietro Andreone, Peter Ferenci, Robert Herring, Donald M. Jensen, Patrick Marcellin, Paul J. Pockros, Maribel Rodríguez-Torres, Lorenzo Rossaro, Vinod K. Rustgi, Thomas Sepe, Mark Sulkowski, Isaac R. Thomason, Eric M. Yoshida, Anna Chan, George Hill

    Published 2012-01-01
    Get full text
    Article

Search Tools: